All In Biotech

Drug Trial Radar · NCT03069352

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

May 29, 2017

Primary completion

Feb 15, 2019

Study completion Aug 21, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • PlaceboDrug

    tablet

  • VenetoclaxDrug

    tablet

  • CytarabineDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.

Locations

109 sites in 24 countries. Site status is shown where the registry gives one.

  • H. Lee Moffit Cancer Center /ID# 164273

    Tampa, Florida

  • Norton Cancer Institute /ID# 158998

    Louisville, Kentucky

  • Univ of Pittsburgh Med Ctr /ID# 158997

    Pittsburgh, Pennsylvania

  • Univ TX, MD Anderson /ID# 159678

    Houston, Texas

  • Swedish Medical Center /ID# 161280

    Seattle, Washington

  • Gundersen Health System /ID# 164272

    La Crosse, Wisconsin

  • Cemic /Id# 159676

    Buenos Aires, Argentina

  • Sanatorio Allende /ID# 159675

    Córdoba, Argentina

  • Calvary Mater Newcastle /ID# 160123

    Waratah, New South Wales, Australia

  • Westmead Hospital /ID# 160121

    Westmead, New South Wales, Australia

  • Alfred Hospital /ID# 160125

    Melbourne, Victoria, Australia

  • Box Hill Hospital /ID# 162920

    Melbourne, Victoria, Australia

  • Universitair Ziekenhuis Antwerpen /ID# 159566

    Edegem, Antwerpen, Belgium

  • Cliniques Universitaires Saint Luc /ID# 159567

    Woluwe-Saint-Lambert, Brussels Capital, Belgium

  • Hospital do Cancer Mae de Deus /ID# 163416

    Porto Alegre, Brazil

  • Centro de Pesquisas Oncologicas /ID# 163567

    Florianópolis, Santa Catarina, Brazil

  • Hospital de Cancer de Barretos /ID# 163568

    Barretos, São Paulo, Brazil

  • Casa de Saúde Santa Marcelina /ID# 163413

    São Paulo, São Paulo, Brazil

  • University of Alberta Hospital /ID# 159646

    Edmonton, Alberta, Canada

  • CISSS de la Monteregie /ID# 159782

    Greenfield Park, Quebec, Canada

  • Hospital Maisonneuve-Rosemont /ID# 159780

    Montreal, Quebec, Canada

  • Hopital Sacre Coeur Montreal /ID# 160982

    Montreal, Quebec, Canada

  • Qilu Hospital of Shandong Univ /ID# 167507

    Jinan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167515

    Wuhan, China

  • Henan Cancer Hospital /ID# 167327

    Zhengzhou, Henan, China

  • Fujian Medical Univ Union Hosp /ID# 167321

    Fuzhou, Fujian, China

  • Nanfang Hospital of Southern Medical University /ID# 170147

    Guangzhou, Guangdong, China

  • Jiangsu Province People's Hospital /ID# 167511

    Nanjing, Jiangsu, China

  • The First Hosp of Jilin Univ /ID# 167512

    Changchun, Jilin, China

  • Ruijin Hospital, Shanghai Jiaotong /ID# 167325

    Shanghai, Shanghai Municipality, China

  • West China Hospital /ID# 167514

    Chengdu, Sichuan, China

  • Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 167509

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 167324

    Hangzhou, Zhejiang, China

  • Fakultni Nemocnice Brno /ID# 159247

    Brno, Czechia

  • Univ Hosp Ostrava-Poruba /ID# 159246

    Ostrava, Czechia

  • Fakult Nem Kralovske Vinohrady /ID# 159248

    Prague, Czechia

  • Centre Hospitalier de la Cote /ID# 159697

    Bayonne, France

  • CHU Bordeaux /ID# 159704

    Pessac, France

  • CHU De Nancy /ID# 159700

    Vandœuvre-lès-Nancy, France

  • Centre Hospitalier Lyon Sud /ID# 159705

    Pierre-Bénite, Rhone, France

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.